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Nineteen eighty-five and 1986 have been consoli-
dation years in which the great advances of the 
early 1980s were brought closer to fruition, The 
single most important advance is the immuno-
suppressive agent, cyclosporine, which was 
developed by Borel et aLI Clinical trials with this 
agent were begun in England by Caine et al2 in 
1978 and a year later in the United States,3 The 
drug was released by the Food and Drug 
Administration for general use in November 
1983. Most commonly, cyclosporine is 
~ used in combination with steroids.3 
~ he effectiveness of cyclosporine precipitated 
an avalanche of cadaveric transplantations of a 
variety of organs, beginning in 1980 and con-
tinuing to the present. Cadaveric renal trans-
plantation has become increasingly accepted, 
not only because the results are improved over 
those with old-style immunosuppression, but 
also because the quality of life is so much better. 
With cyclosporine, dosage of the steroid compo-
nent of therapy is far less than in past times, 
when azathioprine and steroids were used for 
early and maintenance treatment. 
Although cadaveric donors have become the 
principal source of kidneys, some transplant 
surgeons still passionately defend living dona-
tion,4 partly because it makes possible immuno-
logic manipulation of the recipient by the use of 
donor-specific blood transfusions,5 However, 
with the recognition that about 20 living donors 
have died in high-quality centers throughout the 
world, the use of living donors has been increas-
ingly questioned. 
The survival of recipients of cadaveric livers 
has more than doubled since 1980, a viability 
rate largely attributable to cyclosporine.6 A 
smaller but still significant improvement has 
been seen with cardiac transplantation.7 Heart-
lung transplantation and unilateral lung trans-
plantation, which were not feasible previously, 
have become commonplace.8,g 
The most serious limitation to use of cyclospo-
rine is its nephrotoxicity.2,a At first, it was 
thought that the nephrotoxic effect would be 
reversed promptly with dose reduction. How-
ever, with long-term therapy/o,1l there is now 
evidence of permanent renal damage that is 
clearly dose related. Patients maintained with 
small daily doses of the drug for five or six years 
after transplantation of livers have not had any 
late deterioration of renal function. 12 In renal 
recipients treated by us with transplantation 
from late 1979 through 1981, chronic cyclospo-
rine administered in conservative doses has not 
been accompanied by a heavy graft loss as 
might be expected with cumulative cyclosporine 
toxicity, Seventy-seven (83%) of the first 93 
primary cadaveric grafts in these pilot trials 
survived for at least one year. After this, the 
rate of subsequent loss was almost identical to 
that in similar recipients treated in earlier 
timesl3 with azathioprine and prednisone. By 
adding other drugs, which by themselves are 
incapable of allowing long-term graft function, 
doses of cyclosporine can be commensurately 
reduced.a.609 
Monoclonal antilymphocyte globulins, intro-
duced by Co simi et al,14 drawing on the hybrido-
ma techniques of Kohler and Milstein/5 have not 
yet become commercially available. One such 
preparation (the so-called OKT3, Orthoclone) is 
in the last stages of evaluation by the Food and 
Drug Administration and should be made com-
mercially available this year. The new monoclo-
nal antilymphocyte globulins are advocated for 
rejection that has not been easily reversed by 
temporary intensification of steroid therapy. If 
monoclonal antibody therapy is added to base-
line therapy with cyclosporine and steroids, the 
reversal of rejection, upon completion of the 
antibody course, may herald a rejec-M tion-free future for some patients. 16 
ore effective immunosuppression has 
been accompanied by a secondary revolution in 
organ procurement. A technique now exists for 
the safe removal of many organs from the same 
cadaveric donor, without jeopardy to any of 
these organs.17 The technique consists of a 
relatively simple preliminary dissection so that 
cross clamps can be placed on various parts of 
the major thoracic or intra-abdominal vessels, 
allowing core cooling with cold-preservation 
solutions that are infused into the aorta. What 
is needed most urgently is a fundamental 
breakthrough with longer-term preservation 
techniques that would allow vital organs to be 
kept for a week or more. Current methods limit 
preservation of the kidney to not much more 
than two days; for the heart and liver, the safe 
time is considered to be six hours or less. 
The ability to preserve organs for longer 
times would have a revolutionary effect on 
transplantation. A reservoir of stored organs 
could be developed in each country and used for 
international sharing with a global impact. In 
addition, tissue matching might become more 
practical than it has been. However, donor 
availability may remain an important limiting 
factor.1s 
The practical role of tissue matching, no 
matter what the circumstances of preservation, 
has yet to be completely defined. We now realize 
that, in renal transplantation, tissue typing at 
the A and B histocompatibility loci is not a 
prerequisite for, or even a very discriminating 
predictor of, successY Using conventional 
immunosuppression with azathioprine and pred-
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nisone (with or without old-style polyvalent 
ALG), matching of the antigens of the A and B 
loci (four in all) was worth only about 2% points 
cadaveric kidney graft survival per antigen at 
one year.13•19 Recently, a more dramatic effect of 
the antigens of the Dr locus was hoped for, but 
actual experience has not borne out this expec-
tation. 
It has been said that the need for tissue 
matching in kidney transplantation is less with 
improved immunosuppression (cyclosporine and 
steroids). Nevertheless, preliminary data from 
large collections have shown a minor advantage 
of matching. So far, matching has never been 
taken into consideration with heart or liver 
transplantation because of the time limitations 
of acceptable cold ischemia. 
Such improvements as drug combinations 
that include cyclosporine have not benefited 
renal recipients whose serum samples contain 
widely reacting cytotoxic antibodies. These anti-
bodies may render a potential renal recipient 
nontransplantable. A donor whose tissues do not 
react with the antibodies of the recipient (nega-
tive cross match) can never be found. Although 
the dread consequence of a positive cross match, 
namely, hyperacute rejection, is known to be 
precipitated by an antigen-antibody reaction, 
efforts to remove the antibodies with plasma-
pheresis or other techniques have not B proved successful so far. 
. ecause the host's immunologic surveil-
lance is weakened by chronic immunosuppres-
sion, there is a greatly increased incidence of de 
novo malignancies, especially lymphomas, in 
transplant recipients. In recent years, the with-
drawal of immunosuppression has resulted in 
the spontaneous involution of these lesions.20 
This immune manipulation in the treatment of 
cancer seems to have been more firmly estab-
lished in the transplant population than in any 
other clinical setting. 
With the broad advances of the past five or 
six years, hepatic and cardiac transplantations 
have become services, along with renal trans-
plantation, as opposed to experimental proce-
dures. The same has not been possible with 
pancreas transplantation, in which the one-year 
graft survival has remained poor, with an 
unacceptable patient mortality related to the 
procedure itself. 
The romantic newer transplant procedures 
have spawned large numbers of new programs. 
By the end of 1985, there were 40 liver trans-
plant programs in the United States and more 
than 70 teams with pretensions of expertise in 
cardiac transplantation. Debates have flour-
ished about how to discourage this proliferation 
of centers. In addition, there has been increasing 
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interest by government agencies, third-party 
payers, and private agencies in promoting inter-
connecting organ-sharing programs. As a start, 
a highly effective system of voluntary organ 
sharing has already been set up by the existing 
programs. 
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